Search | Clinical Trials Finder

Conditions: Age - Related Macular Degeneration (AMD)
Interventions: Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more

Conditions: Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions: Inhaled nitric oxide, Nitrogen Gas, Crossover iNO; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Minutes to 48 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Glioblastoma Multiforme
Interventions: Bevacizumab; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Metastatic Colorectal Cancer (mCRC)
Interventions: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Sarcoma, Alveolar Soft Part
Interventions: AZD2171; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 16 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Degeneration
Interventions: ranibizumab, verteporfin; Drug
Lead sponsor: Texas Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas

Conditions: Lung Cancer
Interventions: TRC105; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Electronic Health Record Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab (Avastin); Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 30 Weeks and older
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Macular Edema
Interventions: KVD001 Injection, Sham Procedure; Drug · Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more

Conditions: Advanced Solid Tumor
Interventions: BNT326, Pumitamig, Itraconazole, Paroxetine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more

Conditions: Wet AMD
Interventions: Lucentis; Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Neovascular (Wet) AMD
Interventions: ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose; Drug
Lead sponsor: Avirmax Biopharma Inc; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 4
States / cities: Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more

Conditions: EGFR-mutated NSCLC (Disorder)
Interventions: MP0250 DARPin® drug candidate, Osimertinib; Combination Product
Lead sponsor: Molecular Partners AG; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 7 more

Conditions: Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dorzolamide-timolol; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Polypoidal Choroidal Vasculopathy
Interventions: Avacincaptad Pegol; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Macular Degeneration
Interventions: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Age-related Macular Degeneration
Interventions: Fovista® (anti-PDGF BB) plus anti-VEGF; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more

Conditions: Solid Tumor, Adult
Interventions: AXN-2510; Biological
Lead sponsor: Axion Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Huntersville, North Carolina • Dallas, Texas • Houston, Texas + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions: ziv-aflibercept, laboratory biomarker analysis, pharmacological study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Search by objective public record fields.

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Ranibizumab and Reduced Fluence PDT for AMD

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy